Kansenshogaku Zasshi
Online ISSN : 1884-569X
Print ISSN : 0387-5911
ISSN-L : 0387-5911
Comparative Study of BRL28500 (Clavulanic Acid-Ticarcilin) and Piperacillin in the Treatment of Respiratory Tract Infections
Fumio MIKI, Yoshiyasu IKUNO, Eiji INOUE, Akihito MURATA, Shinichi TANIZAWA, Kazuo SAKAMOTO, Akira TAHARA, Akira SAITO, Masumi TAMIZAWA, Yohmei HIRAGA, Kohki KIKUCHI, Tomoko YAMAMOTO, Kazuo TAKABE, Teruo NAKAMURA, Tadashi MIYAZAWA, Toyokazu TAMURA, Katsumi ENDO, Masashi YONEDA, Yasuo IDO, Osamu UEHARA, Katsuhiro OKAMOTO, Morio SAGARA, Tamotsu TAKISHIMA, Shiro IDA, Kiyoshi KONNO, Kotaro OIZUMI, Seiichi AONUMA, Akira WATANABE, Kazuo SATO, Izumi HAYASHI, Masataka KATSU, Shinji OKUI, Mieko KAWAI, Toshio FUKUI, Masaaki ARAKAWA, Koichi WADA, Takao MORIMOTO, Tomoko KABASAWA, Hajimu TAKEDA, Osamu SEKINE, Yoshimaru USUDA, Nobuki AOKI, Tadashi MIYAHARA, Atsushi SAITO, Jingoro SHIMADA, Kohya SHIBA, Hideo IKEMOTO, Kazuyoshi WATANABE, Hiroyuki KOBAYASHI, Kenji TAKAMURA, Masahiko YOSHIDA, Keimei MASHIMO, Yoshiji YAMANE, Toshiharu TOMI, Junzaburo KABE, Hiroyoshi ISHIBASHI, Koichiro KUDO, Takeshi OTA, Hiroichi TANIMOTO, Ryuo NAKATANI, Kunihiko YOSHIMURA, Yoshitaka NAKAMORI, Naohiko CHONABAYASHI, Koichiro NAKATA, Kentaro WATANABE, Masaru KOYAMA, Fukuo IIJIMA, Takashi INAMATSU, Kyoko URAYAMA, Fuyuhiko AZUMA, Yuzo FUNATSU, Ippei FUJIMORI, Yoshio KOBAYASHI, Masanori ADACHI, Kazufuto FUKAYA, Takao OKUBO, Akira ITO, Hiroshi MATSUMOTO, Junichi SUZUKI, Yasuhiro YOSHIIKE, Yuji WATANUKI, Shigeki ODAGIRI, Jun CHIBA, Kaneo SUZUKI, Koou MUROHASHI, Tsutomu FUKUDA, Mitsuyo KIUCHI, Yasuhiko ASHIKARI, Kaoru SHIMOKATA, Saiji YOSHII, Osamu TAKANOU, Shuzo SAKAI, Keisuke NISHIWAKI, Shigeki TAKEURA, Hirotsugu KISHIMOTO, Tatsuo SATAKE, Kenzo TAKAGI, Kenichi YAMAKI, Motohide SASAMOTO, Tomoyasu SASAKI, Toshihiko TAKEUCHI, Masahito KATO, Joichi KATO, Goh ITO, Toshiyuki YAMAMOTO, Kanzo SUZUKI, Kazuhide YAMAMOTO, Satoru ADACHI, Kaoru OYAMA, Kunikazu SUZUKI, Nobuo OTANI, Mitsuru HAYASE, Fumiyuki KUZE, Hiroyuki TSUJINO, Nobuo INABA, Nobuaki IKEDA, Tsuneo MATSUBARA, Shinichi USHIDA, Ryoichi AMITANI, Michiyasu NAKANISHI, Hiroshi OKUBO, Yoshihiro UEDA, Nobuhiro NARITA, Masayoshi SAWAKI, Keiichi MIKASA, Kojiro YASUNAGA, Seibun YONETSU, Yube IIDA, Yoshihiko SAKAKIBARA, Eiroh TSUBURA, Tomoo HAMADA, Koichi FUKUYAMA, Masahiro FUKUOKA, Masami ITO, Fumio HIRAO, Takashi KOMATSU, Nobuo MAEKAWA, Hideki NISHIYAMA, Yujiro SUZUKI, Sadao HORIKAWA, Masakazu TAMURA, Rinzo SOEJIMA, Yoshihito NIKI, Michifumi ADACHI, Yoshihisa NAKAGAWA, Masaru SUMI, Osamu KURIMURA, Hideyo SASAKI, Hirofumi FUKUHARA, Tadao MORIMOTO, Yoshiro SAWAE, Kaoru OKADA, Yukio KUMAGAI, Nobuaki SHIGEMATSU, Hisamichi AIZAWA, Masahide TAKII, Takafumi OHDO, Tomoaki SHINAGAWA, Kohei HARA, Atsushi SAITO, Masaki HIROTA, Keizo YAMAGUCHI, Shigeru KOHNO, Hironobu KAGA, Koichi WATANABE, Kiyo FUJITA, Yasuko UEDA, Kota KOHNO, Keizo MATSUMOTO, Tsuyoshi NAGATAKE, Naoto RIKITOMI, Masaru NASU, Jun GOTO, Yoichiro GOTO, Hideaki SHIGENO, Takayoshi TASHIRO
Author information
Keywords: Respiratory tract infection, BRL28500, Clavulanic acid-Ticarcillin, Piperacillin, Comparative study
JOURNAL FREE ACCESS

1987 Volume 61 Issue 8 Pages 914-943

Details
Download PDF (3557K)
Download citation RIS

(compatible with EndNote, Reference Manager, ProCite, RefWorks)

BIB TEX

(compatible with BibDesk, LaTeX)

Text
How to download citation
Contact us
Abstract

A well-controlled comparative study was undertaken to assess the clinical efficacy and safety of BRL28500 (BRL), a formulation comprising one part of clavulanic acid and 15 parts of ticarcillin, using piperacillin (PIPC) as a reference drug in patients with respiratory tract infections (RTI).
Patients with apparent clinical signs and symptoms of chronic RTI (chronic bronchitis, diffuse panbronchiolitis, infected bronchiectasis, infected pulmonary emphysema, infected pulmonary fibrosis and infected bronchial asthma), acute exacerbation of chronic RTI, bacterial pneumonia and lung abscess were administered 1.6 g of BRL (1.5 g of ticarcillin plus 0.1 g of clavulanic acid) or 2.0 g of PIPC twice daily by intravenous drip infusion for 14 days in principle.
BRL-treated group and PIPC-treated group were compared in terms of clinical efficacy, improvement of clinical symptoms and signs, bacteriological response, incidence of side effects, abnormal changes in laboratory findings and utility. The following results were obtained:
1. BRL and TIPC were administered to a total of 314 patients (BRL to 161 and PIPC to 153). Clinical efficacy was judged in 269 patients (138 on BRL and 131 on PIPC) excluding 45 patients from total patients by the committee.
Incidence of side effects was evaluated in 293 patients (148 on BRL and 145 on PIPC) and abnormal changes in laboratory findings were asessed in 286 patients (141 on BRL and 145 on PIPC).
2. Clinical efficacy rate for the BRL group and PIPC group was 78.8% and 79.4% in total cases, 82.1% (79 patients) and 79.5% (73 patients) in pneumonia and lung abscess and 74.6% (59 patients) and 79.3% (58 patients) in chronic RTI respectively. There was no statistically significant difference between the two groups.
3. As to improvement of clinical symptoms and signs, improvement of ESR in the BRL group was better than that in the PIPC group on 14th day after administration in patients with pneumonia or lung abscess. On the contrary, improvement of rale, WBC and CRP in the BRL group was inferior to those in the PIPC group on 3rd day after administration in patients with chronic RTI. Significant differences were shown in these items between both groups.
4. Bacteriological response was evaluated in 125 patients (68 on BRL and 57 on PIPC) and eradication of causative organisms was 75.0% for the BRL group and 71.9% for the PIPC group, giving no statistical difference between both groups. However, there was a significant difference in preference for BRL to PIPC in terms of eradication of Klebsiella spp. (87.5% for BRL and 16.7% for PIPC).
When causative organisms were classified into two groups according to susceptibility to PIPC, eradication effect of PIPC (94.7%) was superior (p<0.10) to that of BRL (69.6%) in PIPC-sensitive organisms having 50μg/ml of MIC. On the other hand, in PICP-resistant organisms having 50μg/ml of MIC BRL exerted better eradication effect (66.7%) than PIPC (12.5%) and a significant difference was shown between the two groups.
5. In 293 patients assessed incidence of side effects, five patients treated with BRL and eleven patients treated with PIPC complained of side effects and there was no significant difference between both groups.
6. Abnormal changes in laboratory findings were evaluated in 286 patients. Numbers of patients with the abnormal changes were 45 (31.9%) out of 141 patients treated with BRL and 28 (19.3%) out of 145 patients treated with PIPC respectively and the difference was significant (p<0.05) between both groups. Itemized analysis showed that abnormal changes in GPT were found in 26 (18.6%) out to 140 patients treated with BRL and 14 (10.0%) out of 140 patients treated with PIPC and indicated that elevation of BUN were shown only in the PIPC group (4/127, 3.1%), giving tendency of significant difference (p<0.10) on the above items between the two groups.

Content from these authors
© The Japansese Association for Infectious Diseases
Previous article Next article
Favorites & Alerts

Recently viewed articles
Predecessor

Journal of the Japanese Association for Infectious Diseases

Share this page
feedback
 Top